News Story Headlines
December 27, 2023
WAINUA (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
December 21, 2023
US FDA approval based on NEURO-TTRansform Phase III results showing WAINUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life
Additional regulatory reviews underway...
October 12, 2023
2023 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter here!
July 17, 2023
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
PALO ALTO, Calif., July 17, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers. Today, alongside...
July 13, 2023
2023 Summer Newsletter
Be sure to catch up on the latest happenings in our summer newsletter here!
May 5, 2023
Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial
By Shelley Wood MAY 23, 2023
PRAGUE, Czechia—A phase I, randomized, double-blind trial of an intravenous antibody in transthyretin amyloid (ATTR) cardiomyopathy is being hailed as a potential “game changer” after...